Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivo

Benjamin C Tang, Jie Fu, David Neil Watkins, Justin Hanes

Research output: Contribution to journalArticleResearchpeer-review

28 Citations (Scopus)

Abstract

Drug carrier particles composed of poly(ethylene glycol)-co-poly(sebacic acid) (PEG-PSA) have been shown capable of efficient aerosolization into model lungs and the ability to rapidly penetrate human mucus. Here, we develop PEG-PSA particles (Etop/PEG-PSA) that encapsulate up to 40 etoposide by weight in a one step process, release it continuously for 6 days in vitro, and maintain its cytotoxic activity against a human lung tumor cell line in vitro. We further show that Etop/PEG-PSA injected intratumorally effectively suppress human lung tumor growth in a xenograft mouse model, with 100 survival after 31 days. In contrast, 0 survival was observed by day 24 in animals that received free etoposide (either intratumoral or intraperitoneal administration) or placebo particles intratumorally. These findings support PEG-PSA as a drug delivery platform for improved local therapy of cancer.
Original languageEnglish
Pages (from-to)339 - 344
Number of pages5
JournalBiomaterials
Volume31
DOIs
Publication statusPublished - 2010

Cite this

Tang, Benjamin C ; Fu, Jie ; Watkins, David Neil ; Hanes, Justin. / Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivo. In: Biomaterials. 2010 ; Vol. 31. pp. 339 - 344.
@article{5895dffb9f4547259f839327cc99062d,
title = "Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivo",
abstract = "Drug carrier particles composed of poly(ethylene glycol)-co-poly(sebacic acid) (PEG-PSA) have been shown capable of efficient aerosolization into model lungs and the ability to rapidly penetrate human mucus. Here, we develop PEG-PSA particles (Etop/PEG-PSA) that encapsulate up to 40 etoposide by weight in a one step process, release it continuously for 6 days in vitro, and maintain its cytotoxic activity against a human lung tumor cell line in vitro. We further show that Etop/PEG-PSA injected intratumorally effectively suppress human lung tumor growth in a xenograft mouse model, with 100 survival after 31 days. In contrast, 0 survival was observed by day 24 in animals that received free etoposide (either intratumoral or intraperitoneal administration) or placebo particles intratumorally. These findings support PEG-PSA as a drug delivery platform for improved local therapy of cancer.",
author = "Tang, {Benjamin C} and Jie Fu and Watkins, {David Neil} and Justin Hanes",
year = "2010",
doi = "10.1016/j.biomaterials.2009.09.033",
language = "English",
volume = "31",
pages = "339 -- 344",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier",

}

Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivo. / Tang, Benjamin C; Fu, Jie; Watkins, David Neil; Hanes, Justin.

In: Biomaterials, Vol. 31, 2010, p. 339 - 344.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivo

AU - Tang, Benjamin C

AU - Fu, Jie

AU - Watkins, David Neil

AU - Hanes, Justin

PY - 2010

Y1 - 2010

N2 - Drug carrier particles composed of poly(ethylene glycol)-co-poly(sebacic acid) (PEG-PSA) have been shown capable of efficient aerosolization into model lungs and the ability to rapidly penetrate human mucus. Here, we develop PEG-PSA particles (Etop/PEG-PSA) that encapsulate up to 40 etoposide by weight in a one step process, release it continuously for 6 days in vitro, and maintain its cytotoxic activity against a human lung tumor cell line in vitro. We further show that Etop/PEG-PSA injected intratumorally effectively suppress human lung tumor growth in a xenograft mouse model, with 100 survival after 31 days. In contrast, 0 survival was observed by day 24 in animals that received free etoposide (either intratumoral or intraperitoneal administration) or placebo particles intratumorally. These findings support PEG-PSA as a drug delivery platform for improved local therapy of cancer.

AB - Drug carrier particles composed of poly(ethylene glycol)-co-poly(sebacic acid) (PEG-PSA) have been shown capable of efficient aerosolization into model lungs and the ability to rapidly penetrate human mucus. Here, we develop PEG-PSA particles (Etop/PEG-PSA) that encapsulate up to 40 etoposide by weight in a one step process, release it continuously for 6 days in vitro, and maintain its cytotoxic activity against a human lung tumor cell line in vitro. We further show that Etop/PEG-PSA injected intratumorally effectively suppress human lung tumor growth in a xenograft mouse model, with 100 survival after 31 days. In contrast, 0 survival was observed by day 24 in animals that received free etoposide (either intratumoral or intraperitoneal administration) or placebo particles intratumorally. These findings support PEG-PSA as a drug delivery platform for improved local therapy of cancer.

UR - http://www.ncbi.nlm.nih.gov/pubmed/19796810

U2 - 10.1016/j.biomaterials.2009.09.033

DO - 10.1016/j.biomaterials.2009.09.033

M3 - Article

VL - 31

SP - 339

EP - 344

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -